Schizophrenia - Competitive Landscape in 2020

Schizophrenia - Competitive Landscape in 2020
 

Summary
 
GlobalData’s ""Schizophrenia - Competitive Landscape in 2020"" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.
 
5-hydroxytryptamine (5-HT) and dopamine receptors are the major focus of drug developers. There are 143 drugs in the pipeline, 39 of which targets 5-HT or dopamine receptors. Big pharma dominates R&D in this indication, with Otsuka, Johnson & Johnson, Lundbeck, and Roche leading the way. Increasing incidence expected to drive growth in schizophrenia market. The increasing awareness and approval of late-stage pipeline molecules will drive the markets growth over the coming years, but lack of curative treatment and increasing generic penetration will limit the growth.
 
This reports provides a data-driven overview of the current and future competitive landscape in schizophrenia therapeutics.
 
Scope

 
Components of the report include -
- Disease epidemiology
- Marketed drugs assessment
- Pipeline drugs assessment
- Clinical trials assessment
- Commercial assessment
- Social media overview
- Digital marketing overview
 
Reasons to Buy
 
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

 1.Table of Contents
 1.1 Preface
 1.2 Abbreviations
 1.3 Related Reports
 1.4 Upcoming Related Reports
 2 Executive Summary
 2.1 Key Findings
 2.2 Key Events
 3 Introduction
 3.1 Report Scope
 3.2 Disease Overview Epidemiology Overview
 3.3 Epidemiology
 4 Marketed Drugs Assessment
 4.1 Marketed Drugs Overview
 4.2 Marketed Drug Profiles
 5 Pipeline Assessment
 5.1 Pipeline Overview
 5.2 Pipeline Breakdown by Region
 5.3 Pipeline Breakdown by Molecule Type and Target
 5.4 Drug Review Designations
 5.5 Phase Transition Success Rates
 5.6 Likelihood of Approval
 6 Clinical Trial Assessment
 6.1 Clinical Trials Overview by Phase
 6.2 Overview by Region
 6.4 Therapy Area Perspective
 6.4 Leading Sponsors
 6.5 Enrollment Analytics
 6.6 Feasibility Analysis
 7 Commercial Assessment
 7.1 Upcoming Market Catalysts
 8 Social Media and Digital Marketing
 8.1 Key Twitter Chatter
 8.2 Top Branded Websites
 8.3 Trust Flow and Citation Flow
 9 Appendix
 9.1 Methodology
 9.2 About the Authors
 9.3 About GlobalData
 9.4 Contact Us
 9.5 Disclaimer


Schizophrenia (Central Nervous System) - Drugs in Development, 2021

Schizophrenia (Central Nervous System) - Drugs in Development, 2021Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Drugs In Development, 2021, provides an overview of the Schizophrenia

USD 2500 View Report

Obese patients with Schizophrenia - Market Insight, Epidemiology and Market Forecast - 2030

Obese patients with Schizophrenia - Market Insights, Epidemiology, and Market Forecast-2030 report delivers an in-depth understanding of the Obese patients with Schizophrenia , historical and forecasted epidemiology as well

USD 6950 View Report

Gouty Arthritis (Gout) - Competitive Landscape in 2021

Gouty Arthritis (Gout) - Competitive Landscape in 2021GlobalDatas Gouty Arthritis (Gout) - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a

USD 3495 View Report

Huntingtons Disease - Competitive Landscape in 2021

Huntingtons Disease - Competitive Landscape in 2021GlobalDatas Huntingtons Disease - Competitive Landscape in 2021 combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment

USD 3495 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available